OKYO Pharma to present, plan Phase 3 NCP trial

OKYO Pharma highlights upcoming ophthalmology conference presentations and its planned 111-patient global Phase 3 trial of urcosimod for neuropathic corneal pain.

Rhea-AI Filing Summary

OKYO Pharma Ltd (OKYO), a clinical-stage biopharmaceutical company focused on neuropathic corneal pain and anterior segment eye diseases, reported that it will present at the Ophthalmology Futures European Forum and the 5th Annual ESCRS iNovation Day in London in September 2026. These meetings bring together ophthalmologists, clinical innovators, industry leaders, emerging companies and the financial community. OKYO states that ongoing conference participation supports advancement of urcosimod, its lead asset, through a global Phase 3 pivotal NEPTUNE trial for neuropathic corneal pain. The company notes that its presence at these events follows recent positive feedback from a U.S. FDA Type D meeting validating its regulatory and clinical path for urcosimod and the filing of its Annual Report reflecting a strengthened cash position. OKYO also plans to initiate a global Phase 3 pivotal trial in the second half of the year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for neuropathic corneal pain.

Filing Explained

As a Form 6-K, this report furnishes OKYO’s September 9 conference announcement and incorporates it by reference into the company’s active Form F-3 registration statement; the announcement itself concerns planned presentations.

Key Figures

Planned Phase 3 trial enrollment: Approximately 111 patients ESCRS iNovation Day date: September 11, 2026 ESCRS Congress duration: September 11–15, 2026 +1 more

4 metrics

Planned Phase 3 trial enrollment Approximately 111 patients Global Phase 3 pivotal clinical trial of urcosimod for neuropathic corneal pain

ESCRS iNovation Day date September 11, 2026 iNovation Day at ExCeL London, held with the 44th ESCRS Congress

ESCRS Congress duration September 11–15, 2026 44th Congress of the European Society of Cataract and Refractive Surgeons

Form 6-K date September 9, 2026 Date of OKYO Pharma’s news announcement and Form 6-K report

Key Terms

neuropathic corneal pain, Phase 3 pivotal trial, Type D meeting, ESCRS iNovation Day, +1 more

5 terms

neuropathic corneal pain medical

"developing investigational therapies for the treatment of neuropathic corneal pain (NCP)"

Neuropathic corneal pain is chronic, often severe eye pain caused by damage or malfunction in the tiny nerves of the cornea, where the eye surface can feel burning, stinging, or like something is in it despite little visible damage. It matters to investors because it represents a persistent, hard-to-treat medical need that drives demand for new drugs, diagnostics, devices and regulatory approvals, similar to how fixing a frayed electrical wire stops false alarm signals.

Phase 3 pivotal trial medical

"advances urcosimod through its global Phase 3 pivotal trial for neuropathic corneal pain"

A phase 3 pivotal trial is the large, final clinical study that tests whether a new drug or medical treatment works and is safe enough for regulators to approve it for widespread use. Think of it as the full-scale dress rehearsal before a product launches: positive results can unlock regulatory approval and big commercial upside, while failures can halt a program and significantly affect investor value.

Type D meeting regulatory

"positive feedback from its U.S. Food and Drug Administration (FDA) Type D meeting"

ESCRS iNovation Day medical

"present at Ophthalmology Futures Forum and in the 5th Annual ESCRS iNovation Day"

ophthalmic innovation medical

"recognized as a cornerstone event for ophthalmic innovation in Europe"

FAQ

What event is OKYO (OKYO) reporting in this Form 6-K?

OKYO Pharma reports it will present at the Ophthalmology Futures European Forum and the 5th Annual ESCRS iNovation Day in London in September 2026, engaging with clinical, industry, and investment communities in ophthalmology.

What is OKYO (OKYO) developing urcosimod for?

OKYO Pharma is developing urcosimod as an investigational therapy for neuropathic corneal pain (NCP) and anterior segment eye diseases, with urcosimod serving as the company’s lead asset in a planned global Phase 3 pivotal trial.

What Phase 3 trial plans does OKYO (OKYO) disclose for urcosimod?

OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of the year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of neuropathic corneal pain.

What regulatory interaction with the FDA does OKYO (OKYO) reference?

OKYO references recent positive feedback from a U.S. FDA Type D meeting, which it states validated the company’s regulatory and clinical path forward for urcosimod in neuropathic corneal pain.

How does OKYO (OKYO) describe its financial position in this update?

OKYO notes that its participation at these events follows the filing of its Annual Report reflecting a strengthened cash position, indicating an improved liquidity profile as disclosed in that report.

Where are OKYO (OKYO) shares listed for trading?

OKYO Pharma states that its ordinary shares are listed for trading on the Nasdaq Capital Market under the symbol OKYO.

When and where are the ophthalmology meetings mentioned by OKYO (OKYO) taking place?

The Ophthalmology Futures European Forum is on Thursday, September 10 in London, and ESCRS iNovation Day takes place Friday, September 11, 2026 at ExCeL London, held in conjunction with the 44th Congress of the ESCRS running September 11–15, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 07:00 AM Accepted by SEC EDGAR 09/09/2026 - 07:00 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

September 2026

Commission File Number: 001-41386

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On September 9, 2026, OKYO Pharma LTD (the “Company”) issued this 6K announcing that it will present at Ophthalmology Futures Forum and in the 5th Annual ESCRS iNovation Day.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, This report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (Reg. No. 333-293145)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	OKYO Pharma LTD
Date: September 9, 2026	By:	/s/ Keeren Shah
	Name:	Keeren Shah
	Title:	Chief Financial Officer

3

EXHIBIT INDEX

Exhibit No.		Description
99.1		News Announcement, dated September 9, 2026

4

Exhibit 99.1

OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026

Company to engage with the global ophthalmology and investment community as it advances urcosimod through its global Phase 3 pivotal trial for neuropathic corneal pain

London and New York, NY, September 9, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will present at Ophthalmology Futures Forum and in the 5th Annual ESCRS iNovation Day.

Ophthalmology Futures European Forum on Thursday, September 10 in London is where clinical innovators, investors, and industry leaders convene to examine what’s next in ophthalmology and where the next wave of value will be created.

ESCRS iNovation Day, taking place Friday, September 11, 2026 at ExCeL London, United Kingdom, held in conjunction with the 44th Congress of the ESCRS (European Society of Cataract and Refractive Surgeons), running September 11–15, 2026, is recognized as a cornerstone event for ophthalmic innovation in Europe, bringing together ophthalmologists, industry leaders, emerging companies and the financial community.

OKYO’s continued conference participation reflects the clinical, industry, and investor communities central to advancing urcosimod, its lead asset, through its global Phase 3 pivotal NEPTUNE trial for NCP.

The Company’s presence at the events follows recent positive feedback from its U.S. Food and Drug Administration (FDA) Type D meeting, which validated OKYO’s regulatory and clinical path forward for urcosimod, as well as the filing of its Annual Report reflecting a strengthened cash position.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd

Paul Spencer

Business Development and Investor Relations

+44 (0) 207 495 2379

Email: info@okyopharma.com

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 10.3 KB
• EX-99 GRAPHIC 26.1 KB